NCT02858401 - Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2015

Primary Completion Date

February 14, 2019

Study Completion Date

February 14, 2019

Conditions

HIV-1 Infection

Interventions

DRUG

Vesatolimod

Tablet(s) administered orally once every 2 weeks

DRUG

Placebo

Tablet(s) administered orally once every 2 weeks

DRUG

ARV regimen

Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Trial Locations (8)

15213

University of Pittsburgh, Pittsburgh

32803

Orlando Immunology Center Recruiting, Orlando

34982

Midway Immunology & Research Center, Ft. Pierce

43210

Ohio State University Infectious Diseases Research, Columbus

78705

Central Texas Clinical Research, Austin

90069

Mills Clinical Research, Los Angeles

92103

UCSD Antiviral Research Center (AVRC), San Diego

98104

Peter Shalit, MD, Seattle